Recent advances in FLT3 inhibitors for acute myeloid leukemia

被引：16

作者：

Tong, Lexian ^{[1
]}

Li, Xuemei ^{[1
]}

Hu, Yongzhou ^{[1
]}

Liu, Tao ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Pharmaceut Sci, ZJU ENS Joint Lab Med Chem, Zhejiang Prov Key Lab Anticanc Drug Res, Hangzhou 310058, Peoples R China

来源：

FUTURE MEDICINAL CHEMISTRY | 2020年 / 12卷 / 10期

关键词：

acute myeloid leukemia; FLT3; inhibitor; kinase selectivity; SAR-based design; TYROSINE-KINASE INHIBITOR; DEPENDENT DENDRITIC CELLS; POTENT INHIBITOR; IN-VIVO; MULTIKINASE INHIBITOR; JAK2; DISCOVERY; DESIGN; LESTAURTINIB; MUTATION;

D O I：

10.4155/fmc-2019-0365

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Fms-like tyrosine kinase-3 (FLT3) mutations occur in approximately 30% of acute myeloid leukemia (AML) cases, suggesting FLT3 as an attractive target for AML treatment. Early FLT3 inhibitors enhance antileukemia efficacy by inhibiting multiple targets, and thus had stronger off-target activity, increasing their toxicity. Recently, a number of potent and selective FLT3 inhibitors have been developed, many of which are effective against multiple mutations. This review outlines the evolution of AML-targeting FLT3 inhibitors by focusing on their chemotypes, selectivity and activity over FLT3 wild-type and FLT3 mutations as well as new techniques related to FLT3. Compounds that currently enter the late clinical stage or have entered the market are also briefly reported.

引用

页码：961 / 981

页数：21

共 110 条

[51] UNC1062, a new and potent Mer inhibitor [J].

Liu, Jing ;

Zhang, Weihe ;

Stashko, Michael A. ;

DeRyckere, Deborah ;

Cummings, Christopher T. ;

Hunter, Debra ;

Yang, Chao ;

Jayakody, Chatura N. ;

Cheng, Nancy ;

Simpson, Catherine ;

Norris-Drouin, Jacqueline ;

Sather, Susan ;

Kireev, Dmitri ;

Janzen, William P. ;

Earp, H. Shelton ;

Graham, Douglas K. ;

Frye, Stephen V. ;

Wang, Xiaodong .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 65 :83-93

[52] Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia [J].

Liu, Jing ;

Yang, Chao ;

Simpson, Catherine ;

DeRyckere, Deborah ;

Van Deusen, Amy ;

Miley, Michael J. ;

Kireev, Dmitri ;

Norris-Drouin, Jacqueline ;

Sather, Susan ;

Hunter, Debra ;

Korboukh, Victoria K. ;

Patel, Hari S. ;

Janzen, William P. ;

Machius, Mischa ;

Johnson, Gary L. ;

Earp, H. Shelton ;

Graham, Douglas K. ;

Frye, Stephen V. ;

Wang, Xiaodong .

ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (02) :129-134

[53] Medical progress -: Acute myeloid leukemia [J].

Löwenberg, B ;

Downing, JR ;

Burnett, A .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (14) :1051-1062

[54] Novel 1H-Pyrazole-3-carboxamide Derivatives: Synthesis, Anticancer Evaluation and Identification of Their DNA-Binding Interaction [J].

Lu, Yi ;

Ran, Ting ;

Lin, Guowu ;

Jin, Qiaomei ;

Jja, Jianling ;

Li, Hongmei ;

Guo, Hao ;

Lu, Tao ;

Wang, Yue .

CHEMICAL & PHARMACEUTICAL BULLETIN, 2014, 62 (03) :238-246

[55] Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication [J].

Mead, Adam J. ;

Gale, Rosemary E. ;

Kottaridis, Panagiotis D. ;

Matsuda, Satomi ;

Khwaja, Asim ;

Linch, David C. .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (04) :454-460

[56] The novel Trk receptor tyrosine-kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness [J].

Miknyoczki, SJ ;

Dionne, CA ;

Klein-Szanto, AJP ;

Ruggeri, BA .

CELL AND MOLECULAR BIOLOGY OF PANCREATIC CARCINOMA: RECENT DEVELOPMENTS IN RESEARCH AND EXPERIMENTAL THERAPY, 1999, 880 :252-262

[57] The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia [J].

Minson, Katherine A. ;

Smith, Catherine C. ;

DeRyckere, Deborah ;

Libbrecht, Clara ;

Lee-Sherick, Alisa B. ;

Huey, Madeline G. ;

Lasater, Elisabeth A. ;

Kirkpatrick, Gregory D. ;

Stashko, Michael A. ;

Zhang, Weihe ;

Jordan, Craig T. ;

Kireev, Dmitri ;

Wang, Xiaodong ;

Frye, Stephen V. ;

Earp, H. Shelton ;

Shah, Neil P. ;

Graham, Douglas K. .

JCI INSIGHT, 2016, 1 (03)

[58] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia [J].

Mori, Masamichi ;

Kaneko, Naoki ;

Ueno, Yoko ;

Yamada, Masaki ;

Tanaka, Ruriko ;

Saito, Rika ;

Shimada, Itsuro ;

Mori, Kenichi ;

Kuromitsu, Sadao .

INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) :556-565

[59] Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening [J].

Myers, Samuel H. ;

Temps, Carolin ;

Houston, Douglas R. ;

Brunton, Valerie G. ;

Unciti-Broceta, Asier .

JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (05) :2104-2110

[60] An oral androgen receptor PROTAC degrader for prostate cancer. [J].

Neklesa, Taavi K. ;

Snyder, Lawrence B. ;

Bookbinder, Mark ;

Chen, Xin ;

Crew, Andrew P. ;

Crews, Craig M. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)

← 1 2 3 4 5 6 7 8 9 10 →